share_log

NexImmune | S-8 POS: S-8 POS

NexImmune | S-8 POS: S-8 POS

NexImmune | S-8 POS：員工福利計劃證券登記(修正)
美股SEC公告 ·  08/28 04:13
牛牛AI助理已提取核心訊息
NexImmune, Inc., a biopharmaceutical company, has filed Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on August 27, 2024, to deregister all shares of common stock previously registered under three separate Registration Statements on Form S-8. These statements were associated with the company's employee benefit and equity plans from 2017, 2018, and 2021. The deregistration affects a total of 290,210 shares, adjusted for a 1-for-25 reverse stock split that took place on October 18, 2023. This move follows the stockholders' approval of the company's dissolution, liquidation, and winding-up, as disclosed in a Form 8-K filed on August 15, 2024. The company has terminated all offerings of its securities and has removed and withdrawn from registration all unsold securities as of the date of the amendment. The President of NexImmune, Craig Jalbert, signed the amendment, indicating the company's compliance with the requirements for filing and the termination of the effectiveness of the Registration Statements.
NexImmune, Inc., a biopharmaceutical company, has filed Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on August 27, 2024, to deregister all shares of common stock previously registered under three separate Registration Statements on Form S-8. These statements were associated with the company's employee benefit and equity plans from 2017, 2018, and 2021. The deregistration affects a total of 290,210 shares, adjusted for a 1-for-25 reverse stock split that took place on October 18, 2023. This move follows the stockholders' approval of the company's dissolution, liquidation, and winding-up, as disclosed in a Form 8-K filed on August 15, 2024. The company has terminated all offerings of its securities and has removed and withdrawn from registration all unsold securities as of the date of the amendment. The President of NexImmune, Craig Jalbert, signed the amendment, indicating the company's compliance with the requirements for filing and the termination of the effectiveness of the Registration Statements.
NexImmune公司，一家生物製藥公司，於2024年8月27日向美國證券交易委員會（SEC）提交了關於撤銷先前在三份獨立S-8表格註冊的所有普通股股票的後續有效修正案第1號。這些聲明與公司2017年、2018年和2021年的員工福利和股權計劃有關。根據2023年10月18日進行的1比25的股票逆向拆分，共計290,210股股票受到此次撤銷的影響。此舉是在股東批准了公司的清算、清償和終結計劃後進行的，這些計劃在2024年8月15日提交的8-k表格中披露。公司已終止了所有證券的發行，並已於修正案日期從註冊中刪除並撤回了所有未出售的證券。NexImmune總裁Craig Jalbert簽署了這一修正案，表明公司符合申報要求，並終止了註冊聲明的生效。
NexImmune公司，一家生物製藥公司，於2024年8月27日向美國證券交易委員會（SEC）提交了關於撤銷先前在三份獨立S-8表格註冊的所有普通股股票的後續有效修正案第1號。這些聲明與公司2017年、2018年和2021年的員工福利和股權計劃有關。根據2023年10月18日進行的1比25的股票逆向拆分，共計290,210股股票受到此次撤銷的影響。此舉是在股東批准了公司的清算、清償和終結計劃後進行的，這些計劃在2024年8月15日提交的8-k表格中披露。公司已終止了所有證券的發行，並已於修正案日期從註冊中刪除並撤回了所有未出售的證券。NexImmune總裁Craig Jalbert簽署了這一修正案，表明公司符合申報要求，並終止了註冊聲明的生效。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。